The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer

Immunological Reviews

Volumn 222, Issue 1, 2008, Pages 277-286

  Lynch, David H ^a,b  

^a Bainbridge Biopharma Consulting ^*  (United States)

^b Bainbridge Biopharma Consulting   (United States)

Author keywords

4 1BB; Cancer; CD137; Immunotherapy; Monoclonal antibody; TNFR SF

Indexed keywords

ALEMTUZUMAB; CD137 ANTIGEN; CD137 LIGAND; CETUXIMAB; IBRITUMOMAB TIUXETAN; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN EXPRESSION; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MEDICAL RESEARCH; MOLECULAR CLONING; MOLECULAR INTERACTION; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

4-1BB LIGAND; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD137; ANTIGENS, CD40; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR ESCAPE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41149173311     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2008.00621.x     Document Type: Review

References (112)

1. Coley WB. Contribution to the Knowledge of Sarcoma. Ann Surg 1891 14 : 199 220.
2. Coley WB. End results in Hodgkin's disease and lymphosarcoma treated by the mixed toxins of Erysipelas and Bacillus prodigiosus, alone or compined with radiation. Ann Surg 1928 88 : 641 667.
3. O'Malley WE, Achinstein B, Shear MJ. Action of bacterial polysaccharide on tumors. III. Repeated response of Sarcoma 37, in tolerant mice, to Serratia Marcenscens endotoxin. Cancer Res 1963 23 : 890 895.
4. Old LJ. Another chapter in the long history of endotoxin. Nature 1987 330 : 602.
5. Old LJ. Tumor necrosis factor. Sci Am 1988 258 : 59.
6. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Ann Rev Immunol 1989 7 : 625 655.
7. Goodwin RG, et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993 23 : 2631 2641.
8. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 1994 6 : 407 413.
9. Cosman D. A family of ligands for the TNF receptor superfamily. Stem Cells 1994 12 : 440 455.
10. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995 85 : 3378 3404.
11. Baker SJ, Reddy EP. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogene 1996 12 : 1 9.
12. Lotz M, Setareh M, von Kempis J, Schwarz H. The nerve growth factor/tumor necrosis factor receptor family. J Leukoc Biol 1996 60 : 1 7.
13. Ware CF, VanArsdale S, VanArsdale TL. Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem 1996 60 : 47 55.
14. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci USA 1989 86 : 1963 1967.
15. Schwarz H, Valbracht J, Tuckwell J, von Kempis J, Lotz M. ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 1995 85 : 1043 1052.
16. Alderson MR, et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol 1994 24 : 2219 2227.
17. Fransen L, et al. Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res 1985 13 : 4417 4429.
18. Pennica D, Hayflick JS, Bringman TS, Palladino MA, Goeddel DV. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 1985 82 : 6060 6064.
19. Lewis M, et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 1991 88 : 2830 2834.
20. Gardner SM, Mock BA, Hilgers J, Huppi KE, Roeder WD. Mouse lymphotoxin and tumor necrosis factor: structural analysis of the cloned genes, physical linkage, and chromosomal position. J Immunol 1987 139 : 476 483.
21. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994 6 : 1567 1574.
22. Lynch DH, et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994 1 : 131 136.
23. Takahashi T, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994 76 : 969 976.
24. Watanabe-Fukunaga R, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992 148 : 1274 1279.
25. Wiley SR, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995 3 : 673 682.
26. Smith CA, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993 73 : 1349 1360.
27. Bowen MA, Lee RK, Miragliotta G, Nam SY, Podack ER. Structure and expression of murine CD30 and its role in cytokine production. J Immunol 1996 156 : 442 449.
28. Spriggs MK, et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992 176 : 1543 1550.
29. Torres RM, Clark EA. Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation. J Immunol 1992 148 : 620 626.
30. Baum PR, et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J 1994 13 : 3992 4001.
31. Latza U, et al. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol 1994 24 : 677 683.
32. Rabu C, Quemener A, Jacques Y, Echasserieau K, Vusio P, Lang F. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem 2005 280 : 41472 41481.
33. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Semin Immunol 1998 10 : 481 489.
34. Pollok KE, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993 150 : 771 781.
35. Hurtado JC, Kim SH, Pollok KE, Lee ZH, Kwon BS. Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28. J Immunol 1995 155 : 3360 3367.
36. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998 190 : 167 172.
37. Kim JO, Kim HW, Baek KM, Kang CY. NF-kappaB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells. FEBS Lett 2003 541 : 163 170.
38. Kim YJ, et al. Novel T cell antigen 4-1BB associates with the protein tyrosine kinase p56lck1. J Immunol 1993 151 : 1255 1262.
39. Arch RH, Thompson CB. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 1998 18 : 558 565.
40. Cannons JL, Choi Y, Watts TH. Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response. J Immunol 2000 165 : 6193 6204.
41. Gramaglia I, Cooper D, Miner KT, Kwon BS, Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur J Immunol 2000 30 : 392 402.
42. Shuford WW, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997 186 : 47 55.
43. Schwarz H, Blanco FJ, von Kempis J, Valbracht J, Lotz M. ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival. Blood 1996 87 : 2839 2845.
44. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997 158 : 2600 2609.
45. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999 162 : 5037 5040.
46. Laderach D, Movassagh M, Johnson A, Mittler RS, Galy A. 4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells. Int Immunol 2002 14 : 1155 1167.
47. L and Bfl-1. J Immunol 2002 169 : 4882 4888.
48. Langstein J, Schwarz H. Identification of CD137 as a potent monocyte survival factor. J Leukoc Biol 1999 65 : 829 833.
49. DeBenedette MA, et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 1999 163 : 4833 4841.
50. Vinay DS, Wolisi GO, Yu KY, Choi BK, Kwon BS. Immunity in the absence of CD28 and CD137 (4-1BB) molecules. Immunol Cell Biol 2003 81 : 176 184.
51. Halstead ES, Mueller YM, Altman JD, Katsikis PD. In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses. Nat Immunol 2002 3 : 536 541.
52. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996 14 : 233 258.
53. Chen L, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994 179 : 523 532.
54. Strome SE, et al. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma. J Immunother 2000 23 : 430 437.
55. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998 392 : 245 252.
56. Satthaporn S, Eremin O. Dendritic cells (I): biological functions. J R Coll Surg Edinb 2001 46 : 9 19.
57. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997 186 : 1183 1187.
58. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992 356 : 607 609.
59. Frauwirth KA, Alegre ML, Thompson CB. CTLA-4 is not required for induction of CD8(+) T cell anergy in vivo. J Immunol 2001 167 : 4936 4941.
60. Deeths MJ, Kedl RM, Mescher MF. CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol 1999 163 : 102 110.
61. Chai JG, et al. Critical role of costimulation in the activation of naive antigen-specific TCR transgenic CD8+ T cells in vitro. J Immunol 1999 163 : 1298 1305.
62. Noble A. Review article: molecular signals and genetic reprogramming in peripheral T-cell differentiation. Immunology 2000 101 : 289 299.
63. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998 95 : 10067 10071.
64. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999 190 : 355 366.
65. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001 19 : 565 594.
66. Hurwitz AA, Kwon ED, van Elsas A. Costimulatory wars: the tumor menace. Curr Opin Immunol 2000 12 : 589 596.
67. Zhan Y, Corbett AJ, Brady JL, Sutherland RM, Lew AM. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation. J Immunol 2000 165 : 3612 3619.
68. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993 259 : 368 370.
69. Yu X, Abe R, Hodes RJ. The role of B7-CD28 co-stimulation in tumor rejection. Int Immunol 1998 10 : 791 797.
70. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 1997 3 : 625 631.
71. Borges L, et al. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol 1999 163 : 1289 1297.
72. Kinoshita Y, et al. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. J Immunother 2001 24 : 205 211.
73. Eck SC, Turka LA. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T cells. Cancer Immunol Immunother 1999 48 : 336 341.
74. McKenna HJ. Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells. Curr Opin Hematol 2001 8 : 149 154.
75. Sayers TJ, Wiltrout TA, McCormick K, Husted C, Wiltrout RH. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo. Cancer Res 1990 50 : 5414 5420.
76. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996 88 : 38 43.
77. Melero I, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997 3 : 682 685.
78. Miller RE, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002 169 : 1792 1800.
79. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 2000 288 : 675 678.
80. Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol 2007 125 : 76 87.
81. Ito F, et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 2004 64 : 8411 8419.
82. Xu DP, Sauter BV, Huang TG, Meseck M, Woo SL, Chen SH. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther 2005 12 : 1526 1533.
83. Mittler RS, et al. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res 2004 29 : 197 208.
84. Jure-Kunkel MN, et al. Functional characterization of fully human anti-CD137 antibodies. P Am Assoc Canc Res 2006 1117.
85. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998 28 : 1116 1121.
86. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999 162 : 5003 5010.
87. Mogi S, et al. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology 2000 101 : 541 547.
88. Caruso M, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996 93 : 11302 11306.
89. Divino CM, Chen SH, Yang W, Thung S, Brower ST, Woo SL. Characterization of a novel immunocytolytic factor secreted by pancreatic adenocarcinoma. Oncol Res 1999 11 : 489 495.
90. Walunas TL, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994 1 : 405 413.
91. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995 182 : 459 465.
92. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997 7 : 445 450.
93. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002 3 : 611 618.
94. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006 90 : 297 339.
95. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005 23 : 515 548.
96. Guleria I, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 2005 202 : 231 237.
97. Habicht A, et al. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol 2007 179 : 5211 5219.
98. Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion [Erratum in: Nat Med 2002;8:1039]. Nat Med 2002 8 : 793 800.
99. Hirano F, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005 65 : 1089 1096.
100. Xiao H, et al. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 2007 13 : 1823 1830.
101. Blazar BR, Kwon BS, Panoskaltsis-Mortari A, Kwak KB, Peschon JJ, Taylor PA. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients. J Immunol 2001 166 : 3174 3183.
102. Foell J, et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB × NZW F1 mice. J Clin Invest 2003 111 : 1505 1518.
103. Lee J, et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol Lett 2005 101 : 210 216.
104. Foell JL, et al. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 2004 113 : 89 98.
105. Seo SK, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis [Erratum in: Nat Med 2004;10:1261]. Nat Med 2004 10 : 1088 1094.
106. Vinay DS, Kim JD, Kwon BS. Amelioration of mercury-induced autoimmunity by 4-1BB. J Immunol 2006 177 : 5708 5717.
107. Wehler TC, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007 109 : 365 373.
108. Amrolia PJ, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses [Erratum in: Blood 2004;104:1605]. Blood 2003 102 : 2292 2299.
109. Shin SM, Kim YH, Choi BK, Kwon PM, Lee HW, Kwon BS. 4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation. J Leukoc Biol 2007 81 : 1455 1465.
110. Choi BK, Asai T, Vinay DS, Kim YH, Kwon BS. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine 2006 34 : 233 242.
111. Myers L, Takahashi C, Mittler RS, Rossi RJ, Vella AT. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol 2004 173 : 3002 3012.
112. Myers L, Croft M, Kwon BS, Mittler RS, Vella AT. Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol 2005 174 : 7625 7632.